Clinical Trials for Phanes Therapeutics

Explore 3 clinical trials worldwide

Showing 1-3 of 3 trials

Active filters:Status: Recruiting, Active, not recruiting, Enrolling by invitation, Not yet recruitingSponsor: Phanes Therapeutics

Clinical Trials (3)

NCT05652686
A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)
PHASE1/PHASE2Recruiting
203 participants
Started: Sep 5, 2023 · Completed: Aug 31, 2028
6 conditions2 sponsors12 locations
NCT05482893
Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or ICI, for the Treatment of Patients With Advanced Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)
PHASE1/PHASE2Recruiting
258 participants
Started: Mar 15, 2023 · Completed: Apr 30, 2028
3 conditions2 sponsors11 locations
NCT05431270
Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 MAb, Administered Alone and in Combination with a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)
PHASE1/PHASE2Recruiting
40 participants
Started: Aug 11, 2022 · Completed: Aug 31, 2028
2 conditions2 sponsors6 locations